StreetInsider.com News Articles

GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates

Wed, 08 Jul 2026 13:11:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

Cash Position as of June 30, 2026

GenSight Biologics’ cash and cash equivalents totaled €1.7 million as of June 30, 2026, compared to €3.2 million as of March 31, 2026.

The operating cash burn in the second quarter of 2026 mainly reflects the management of GS010/LUMEVOQ®, Early Access Programs, primarily in France and Israel, as

GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates

Wed, 08 Jul 2026 13:11:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

Cash Position as of June 30, 2026

GenSight Biologics’ cash and cash equivalents totaled €1.7 million as of June 30, 2026, compared to €3.2 million as of March 31, 2026.

The operating cash burn in the second quarter of 2026 mainly reflects the management of GS010/LUMEVOQ®, Early Access Programs, primarily in France and Israel, as

GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates

Wed, 08 Jul 2026 13:11:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

Cash Position as of June 30, 2026

GenSight Biologics’ cash and cash equivalents totaled €1.7 million as of June 30, 2026, compared to €3.2 million as of March 31, 2026.

The operating cash burn in the second quarter of 2026 mainly reflects the management of GS010/LUMEVOQ®, Early Access Programs, primarily in France and Israel, as

GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates

Wed, 08 Jul 2026 13:11:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

Cash Position as of June 30, 2026

GenSight Biologics’ cash and cash equivalents totaled €1.7 million as of June 30, 2026, compared to €3.2 million as of March 31, 2026.

The operating cash burn in the second quarter of 2026 mainly reflects the management of GS010/LUMEVOQ®, Early Access Programs, primarily in France and Israel, as

GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates

Wed, 08 Jul 2026 13:11:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

Cash Position as of June 30, 2026

GenSight Biologics’ cash and cash equivalents totaled €1.7 million as of June 30, 2026, compared to €3.2 million as of March 31, 2026.

The operating cash burn in the second quarter of 2026 mainly reflects the management of GS010/LUMEVOQ®, Early Access Programs, primarily in France and Israel, as

GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates

Wed, 08 Jul 2026 13:11:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

Cash Position as of June 30, 2026

GenSight Biologics’ cash and cash equivalents totaled €1.7 million as of June 30, 2026, compared to €3.2 million as of March 31, 2026.

The operating cash burn in the second quarter of 2026 mainly reflects the management of GS010/LUMEVOQ®, Early Access Programs, primarily in France and Israel, as

GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates

Wed, 08 Jul 2026 13:11:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

Cash Position as of June 30, 2026

GenSight Biologics’ cash and cash equivalents totaled €1.7 million as of June 30, 2026, compared to €3.2 million as of March 31, 2026.

The operating cash burn in the second quarter of 2026 mainly reflects the management of GS010/LUMEVOQ®, Early Access Programs, primarily in France and Israel, as

GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates

Wed, 08 Jul 2026 13:11:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

Cash Position as of June 30, 2026

GenSight Biologics’ cash and cash equivalents totaled €1.7 million as of June 30, 2026, compared to €3.2 million as of March 31, 2026.

The operating cash burn in the second quarter of 2026 mainly reflects the management of GS010/LUMEVOQ®, Early Access Programs, primarily in France and Israel, as

GenSight Biologics Announces the Results of its Combined General Meeting of May 19, 2026

Wed, 20 May 2026 12:00:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that all 28 resolutions submitted for shareholders’ vote at the Combined Shareholders’ Meeting held on May 19, 2026, and chaired by Laurence Rodriguez, Chief Executive Officer of the Company, were approved.

During the General Meeting, Ms. Rodriguez answered shareholders’ questions together with Dr. Magali Taiel, Chief Medical Officer, and Jan Eryk Umiastowski, Chief Financial Officer.

The approved resolutions notably include financial delegations that would enable the Company

GenSight Biologics Announces the Results of its Combined General Meeting of May 19, 2026

Wed, 20 May 2026 12:00:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

During the General Meeting, Ms. Rodriguez answered shareholders’ questions together with Dr. Magali Taiel, Chief Medical Officer, and Jan Eryk Umiastowski, Chief Financial Officer.

The approved resolutions notably include financial delegations that would enable the Company

GenSight Biologics Announces the Results of its Combined General Meeting of May 19, 2026

Wed, 20 May 2026 12:00:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

During the General Meeting, Ms. Rodriguez answered shareholders’ questions together with Dr. Magali Taiel, Chief Medical Officer, and Jan Eryk Umiastowski, Chief Financial Officer.

The approved resolutions notably include financial delegations that would enable the Company

GenSight Biologics Announces the Results of its Combined General Meeting of May 19, 2026

Wed, 20 May 2026 12:00:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

During the General Meeting, Ms. Rodriguez answered shareholders’ questions together with Dr. Magali Taiel, Chief Medical Officer, and Jan Eryk Umiastowski, Chief Financial Officer.

The approved resolutions notably include financial delegations that would enable the Company

GenSight Biologics to Hold its Combined General Meeting on May 19, 2026

Mon, 18 May 2026 12:30:00 -0400

Combined General Meeting on May 19, 2026
Key operational developments in 2025 and 2026

PARIS--(BUSINESS WIRE)-- Regulatory News:

GenSight Biologics (the “Company”) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharmaceutical company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that its Combined General Meeting will be held tomorrow, Tuesday, May 19, 2026, at 2:00 p.m. CEST and will be broadcast live via the following link: GENSIGHT BIOLOGICS - Assemblée générale 2026.

On this occasion, Laurence Rodriguez, Chief Executive Officer, will present an overview of the

GenSight Biologics to Hold its Combined General Meeting on May 19, 2026

Mon, 18 May 2026 12:30:00 -0400

Combined General Meeting on May 19, 2026
Key operational developments in 2025 and 2026

PARIS--(BUSINESS WIRE)-- Regulatory News:

On this occasion, Laurence Rodriguez, Chief Executive Officer, will present an overview of the

GenSight Biologics to Hold its Combined General Meeting on May 19, 2026

Mon, 18 May 2026 12:30:00 -0400

Combined General Meeting on May 19, 2026
Key operational developments in 2025 and 2026

PARIS--(BUSINESS WIRE)-- Regulatory News:

On this occasion, Laurence Rodriguez, Chief Executive Officer, will present an overview of the

GenSight Biologics to Hold its Combined General Meeting on May 19, 2026

Mon, 18 May 2026 12:30:00 -0400

Combined General Meeting on May 19, 2026
Key operational developments in 2025 and 2026

PARIS--(BUSINESS WIRE)-- Regulatory News:

On this occasion, Laurence Rodriguez, Chief Executive Officer, will present an overview of the

GenSight Biologics Announces Publication on Matching-Adjusted Indirect Comparison of Leber Hereditary Optic Neuropathy Treatments

Mon, 11 May 2026 12:30:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the publication of a Matching Adjusted Indirect Comparison (MAIC) of outcomes from the clinical trials of GS010/LUMEVOQ®, the Company’s gene therapy investigational product for the treatment of ND4-LHON (Leber Hereditary Optic Neuropathy),1 and idebenone, the only approved treatment for LHON. The study was published in the April 2026 issue of the journal British Journal of Ophthalmology.

The full article, named "Efficacy of lenadogene nolparvovec gene

GenSight Biologics Announces Publication on Matching-Adjusted Indirect Comparison of Leber Hereditary Optic Neuropathy Treatments

Mon, 11 May 2026 12:30:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the publication of a Matching Adjusted Indirect Comparison (MAIC) of outcomes from the clinical trials of GS010/LUMEVOQ®, the Company’s gene therapy investigational product for the treatment of ND4-LHON (Leber Hereditary Optic Neuropathy),1 and idebenone, the only approved treatment for LHON. The study was published in the April 2026 issue of the journal British Journal of Ophthalmology.
The full article, named "Efficacy of lenadogene nolparvovec gene

GenSight Biologics Announces Publication on Matching-Adjusted Indirect Comparison of Leber Hereditary Optic Neuropathy Treatments

Mon, 11 May 2026 12:30:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the publication of a Matching Adjusted Indirect Comparison (MAIC) of outcomes from the clinical trials of GS010/LUMEVOQ®, the Company’s gene therapy investigational product for the treatment of ND4-LHON (Leber Hereditary Optic Neuropathy),1 and idebenone, the only approved treatment for LHON. The study was published in the April 2026 issue of the journal British Journal of Ophthalmology.
The full article, named "Efficacy of lenadogene nolparvovec gene

GenSight Biologics Announces Publication on Matching-Adjusted Indirect Comparison of Leber Hereditary Optic Neuropathy Treatments

Mon, 11 May 2026 12:30:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the publication of a Matching Adjusted Indirect Comparison (MAIC) of outcomes from the clinical trials of GS010/LUMEVOQ®, the Company’s gene therapy investigational product for the treatment of ND4-LHON (Leber Hereditary Optic Neuropathy),1 and idebenone, the only approved treatment for LHON. The study was published in the April 2026 issue of the journal British Journal of Ophthalmology.
The full article, named "Efficacy of lenadogene nolparvovec gene

GenSight Biologics Announces Publication on Matching-Adjusted Indirect Comparison of Leber Hereditary Optic Neuropathy Treatments

Mon, 11 May 2026 12:30:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the publication of a Matching Adjusted Indirect Comparison (MAIC) of outcomes from the clinical trials of GS010/LUMEVOQ®, the Company’s gene therapy investigational product for the treatment of ND4-LHON (Leber Hereditary Optic Neuropathy),1 and idebenone, the only approved treatment for LHON. The study was published in the April 2026 issue of the journal British Journal of Ophthalmology.
The full article, named "Efficacy of lenadogene nolparvovec gene

GenSight Biologics Announces Publication on Matching-Adjusted Indirect Comparison of Leber Hereditary Optic Neuropathy Treatments

Mon, 11 May 2026 12:30:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the publication of a Matching Adjusted Indirect Comparison (MAIC) of outcomes from the clinical trials of GS010/LUMEVOQ®, the Company’s gene therapy investigational product for the treatment of ND4-LHON (Leber Hereditary Optic Neuropathy),1 and idebenone, the only approved treatment for LHON. The study was published in the April 2026 issue of the journal British Journal of Ophthalmology.
The full article, named "Efficacy of lenadogene nolparvovec gene

GenSight Biologics Announces Publication on Matching-Adjusted Indirect Comparison of Leber Hereditary Optic Neuropathy Treatments

Mon, 11 May 2026 12:30:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the publication of a Matching Adjusted Indirect Comparison (MAIC) of outcomes from the clinical trials of GS010/LUMEVOQ®, the Company’s gene therapy investigational product for the treatment of ND4-LHON (Leber Hereditary Optic Neuropathy),1 and idebenone, the only approved treatment for LHON. The study was published in the April 2026 issue of the journal British Journal of Ophthalmology.
The full article, named "Efficacy of lenadogene nolparvovec gene

GenSight Biologics Announces Publication on Matching-Adjusted Indirect Comparison of Leber Hereditary Optic Neuropathy Treatments

Mon, 11 May 2026 12:30:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the publication of a Matching Adjusted Indirect Comparison (MAIC) of outcomes from the clinical trials of GS010/LUMEVOQ®, the Company’s gene therapy investigational product for the treatment of ND4-LHON (Leber Hereditary Optic Neuropathy),1 and idebenone, the only approved treatment for LHON. The study was published in the April 2026 issue of the journal British Journal of Ophthalmology.
The full article, named "Efficacy of lenadogene nolparvovec gene

GenSight Biologics Announces Annual General Meeting to Take Place on May 19, 2026

Tue, 28 Apr 2026 14:35:00 -0400

Procedures for obtaining preparatory documents for the General Meeting are described below.

PARIS--(BUSINESS WIRE)-- Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will hold its Annual General Meeting on May 19, 2026, at 2:00 pm CEST at the Company’s headquarters at 74 rue du Faubourg Saint-Antoine, 75012 Paris, France.
The General Meeting will also be webcast live for shareholders at the following link: https://gensightbiologics.engagestream.euronext.com/2026-05-19-ag.
The notice containing the agenda and draft resolutions